Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson; Anat Achiron; Lars Alfredsson; Thomas Berger; David Brassat; Andrew Chan; Giancarlo Comi; Mefkure Eraksoy; Harald Hegen; Jan Hillert; Poul Erik Hyldgaard Jensen; Lucia Moiola; Kjell-Morten Myhr; Annette Oturai; Sven Schippling; Aksel Siva; Per Soelberg Sorensen; Anne-Kathrin Trampe; Thomas Weber; James Potts; Tatiana Plavina; Dominic Paes; Meena Subramanyam; Heinz Wiendl; Hussein Dib; Deniz Uren; Bernhard Hemmer; Dorothea Buck

doi:10.1177/1352458513477925

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson, Anat Achiron, Lars Alfredsson, Thomas Berger, David Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen, Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg Sorensen, Anne-Kathrin Trampe, Thomas Weber, James PottsTatiana Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib, Deniz Uren, Bernhard Hemmer, Dorothea Buck

Department of Clinical Medicine

79 Citations (Scopus)

Abstract

JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

Original language	English
Journal	Multiple Sclerosis
Volume	19
Issue number	11
Pages (from-to)	1533-1538
Number of pages	6
ISSN	1352-4585
DOIs	https://doi.org/10.1177/1352458513477925
Publication status	Published - Oct 2013

Access to Document

10.1177/1352458513477925

Cite this

Olsson, T., Achiron, A., Alfredsson, L., Berger, T., Brassat, D., Chan, A., Comi, G., Eraksoy, M., Hegen, H., Hillert, J., Jensen, P. E. H., Moiola, L., Myhr, K-M., Oturai, A., Schippling, S., Siva, A., Sorensen, P. S., Trampe, A-K., Weber, T., ... Buck, D. (2013). Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis, 19(11), 1533-1538. https://doi.org/10.1177/1352458513477925

Olsson, T, Achiron, A, Alfredsson, L, Berger, T, Brassat, D, Chan, A, Comi, G, Eraksoy, M, Hegen, H, Hillert, J, Jensen, PEH, Moiola, L, Myhr, K-M, Oturai, A, Schippling, S, Siva, A, Sorensen, PS, Trampe, A-K, Weber, T, Potts, J, Plavina, T, Paes, D, Subramanyam, M, Wiendl, H, Dib, H, Uren, D, Hemmer, B & Buck, D 2013, 'Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort', Multiple Sclerosis, vol. 19, no. 11, pp. 1533-1538. https://doi.org/10.1177/1352458513477925

@article{26c1146b2be6445288d9f4941bd69f19,

title = "Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort",

abstract = "JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.",

author = "Tomas Olsson and Anat Achiron and Lars Alfredsson and Thomas Berger and David Brassat and Andrew Chan and Giancarlo Comi and Mefkure Eraksoy and Harald Hegen and Jan Hillert and Jensen, {Poul Erik Hyldgaard} and Lucia Moiola and Kjell-Morten Myhr and Annette Oturai and Sven Schippling and Aksel Siva and Sorensen, {Per Soelberg} and Anne-Kathrin Trampe and Thomas Weber and James Potts and Tatiana Plavina and Dominic Paes and Meena Subramanyam and Heinz Wiendl and Hussein Dib and Deniz Uren and Bernhard Hemmer and Dorothea Buck",

year = "2013",

month = oct,

doi = "10.1177/1352458513477925",

language = "English",

volume = "19",

pages = "1533--1538",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "11",

}

TY - JOUR

T1 - Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

AU - Olsson, Tomas

AU - Achiron, Anat

AU - Alfredsson, Lars

AU - Berger, Thomas

AU - Brassat, David

AU - Chan, Andrew

AU - Comi, Giancarlo

AU - Eraksoy, Mefkure

AU - Hegen, Harald

AU - Hillert, Jan

AU - Jensen, Poul Erik Hyldgaard

AU - Moiola, Lucia

AU - Myhr, Kjell-Morten

AU - Oturai, Annette

AU - Schippling, Sven

AU - Siva, Aksel

AU - Sorensen, Per Soelberg

AU - Trampe, Anne-Kathrin

AU - Weber, Thomas

AU - Potts, James

AU - Plavina, Tatiana

AU - Paes, Dominic

AU - Subramanyam, Meena

AU - Wiendl, Heinz

AU - Dib, Hussein

AU - Uren, Deniz

AU - Hemmer, Bernhard

AU - Buck, Dorothea

PY - 2013/10

Y1 - 2013/10

N2 - JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

AB - JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

U2 - 10.1177/1352458513477925

DO - 10.1177/1352458513477925

M3 - Journal article

C2 - 23459571

SN - 1352-4585

VL - 19

SP - 1533

EP - 1538

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 11

ER -

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Abstract

Access to Document

Fingerprint

Cite this